British biotech Levicept has appointed Eliot Forster as chief executive, with the company’s founder, Simon Westbrook, taking up the role of chief scientific officer.
Headquartered in Sandwich, Kent, the company is developing LEVI-04, a novel biologic for the treatment of chronic pain.
The candidate is currently in mid-stage testing, with an ongoing trial evaluating its impact in people with osteoarthritis of the knee.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze